• Cognizant Technology Solutions recently announced it will support Kyowa Kirin’s deployment of Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan, integrating experimental design, data capture and workflow automation into a single environment.
• The partnership highlights Cognizant’s role in enabling AI-powered, end-to-end digital transformation for complex pharmaceutical research operations, from centralized data management to automated molecular design workflows.
• We’ll now examine how this expanded AI-led life sciences implementation, particularly Cognizant’s end-to-end Benchling support, may influence its investment narrative.

Invest in the nuclear renaissance through our list of 92 elite…